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Abstract 
Metabolic acidosis is common in advanced chronic kidney disease, and has been associated with a 
range of physiological derangements of importance to the health of older people. These include 
associations with skeletal muscle weakness, cardiovascular risk factors, and bone and mineral 
disorders that may lead to fragility fractures. Although metabolic acidosis is associated with 
accelerated decline in kidney function, end stage renal failure is a much less common outcome in 
older, frail patients than cardiovascular death. Correction of metabolic acidosis using bicarbonate 
therapy is commonly employed, but the existing evidence is insufficient to know whether such therapy 
is of net benefit to older people. Bicarbonate is bulky and awkward to take, may impose additional 
sodium load with effects on fluid retention and blood pressure, and may cause gastrointestinal side 
effects. Trial data to date suggests potential benefits of bicarbonate therapy on progression of renal 
disease and nutrition, but trials have not as yet been published examining the effect of bicarbonate 
therapy across a range of domains relevant to the health of older people. Fortunately, a number of 
trials are now underway that should allow us to ascertain whether bicarbonate therapy can improve 
physical function, quality of life, vascular, bone and kidney health in older people, and hence decide 
whether any benefits seen outweigh adverse effects and additional treatment burden in this 
vulnerable group of patients. 
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Introduction 
Chronic kidney disease (CKD) becomes more common with increasing age [1], and although the 
proportion of patients with advanced CKD (glomerular filtration rate [GFR] <30 mL/min/1.73 m2) is a 
relatively small proportion of the total, population ageing and age-specific increases in prevalence [2, 
3]  are likely to combine to increase overall numbers in future. Managing CKD in older people presents 
a different set of challenges to management in younger people – the presence of multimorbidity, 
polypharmacy, impaired homeostasis across multiple organ systems, and differences in patients’ 
expectations and the aims of therapy all combine to produce a situation in which the existing evidence 
base for treatment is often of limited help [4]. Metabolic acidosis becomes more common with 
advancing CKD, and emerging evidence links acidosis to a range of outcomes that are highly relevant 
to the healthcare priorities of older people, including effects on bone and mineral metabolism, 
cardiovascular health and kidney disease progression. Intuitively, correction of acidosis should be 
beneficial. In this review, we examine the effects of CKD-associated metabolic acidosis on health and 
physical function in older people, and consider whether the current evidence is sufficient to support 
a net benefit of treatment across a range of outcomes that are important to older people with CKD. 
 
Observational data 
How common is acidosis? 
Fixed (non-volatile) acids, notably sulphuric and phosphoric acids, accumulate as a normal 
consequence of protein metabolism and of intake in the diet. The kidney maintains acid-base balance 
by eliminating excess acid: this is achieved by reclamation of filtered bicarbonate and through 
ammoniagenesis. These processes become impaired in kidney disease, resulting in acidosis. Acidosis 
is not usually measured directly in epidemiological studies, but is inferred by the presence of a low 
serum bicarbonate concentration. At all ages, acidosis becomes more common with declining GFR [5], 
with a marked increase in the prevalence of acidosis as GFR falls below 45 mL/min/1.73 m2; recent 
data [6] from a representative CKD cohort showed that 13% of those with eGFR 30-59 mL/min/1.73m2 
had a serum bicarbonate concentration <22 mmol/L, rising to 37% of those with eGFR 15-29 
mL/min/1.73m2. Similar rates have been shown in other cohorts, depending on the population and 
the bicarbonate concentration cutoffs used to define acidosis. 
 
It is less clear whether older people are more or less likely to have low serum bicarbonate 
concentrations than younger people; in the study by Raphael et al [6], older age was associated with 
a slightly higher serum bicarbonate. However, other studies have found either no effect [7], that older 
age is associated with increased rates of low bicarbonate [8], or that younger age is associated with 
increased rates of low bicarbonate [5, 9]. Other factors that have been shown to impact on serum 
bicarbonate concentrations include medications (e.g. diuretics, renin-angiotensin system blockers) [6, 
8]. This is important as rates of concomitant medication use by older people with CKD are high, and 
are hence likely to have an effect on how commonly low bicarbonate levels occur. Variations in dietary 
acid load may also have an effect. Amongst >30,000 individuals enrolled in the National Health and 
Nutrition Examination Survey (NHANES), the prevalence of acidosis (serum bicarbonate <22 mmol/L) 
was decreased amongst older compared to younger individuals with low GFR: the authors postulate 
that this could reflect increased thiazide diuretic usage in older people [5]. 
 
 
Association with progression of renal dysfunction 
Acidosis has deleterious effects on renal function, and appears to potentiate tubular injury. A range 
of mechanisms have been postulated, including intrarenal calcium deposition, complement activation 
and neurohormonal activation, reviewed elsewhere in more detail [10]. Acidosis has direct effects on 
muscle function, in part by leading to increased breakdown of muscle protein [11]. 
 Several studies have linked the presence of low serum bicarbonate concentrations to accelerated 
decline in renal function. These associations extend even to individuals without established CKD. In 
the Multi-ethnic Study of Atherosclerosis (MESA) all participants had baseline GFR levels >60 
ml/min/1.73 m2, but participants with a serum bicarbonate concentrations of <21 mmol/L were 35% 
more likely to experience rapid (>5%/yr) decline in kidney function compared to those with serum 
bicarbonate concentrations of 23-24 mmol/L [12]. Similar findings apply to older people with 
preserved kidney function. In the Health, Aging and Body composition study [13], participants aged 
70-79 years with serum bicarbonate <23 mmol/L had a more rapid decline in GFR compared to those 
with serum bicarbonate concentrations between 23 and 28 mmol/L; this association remained after 
adjustment for baseline factors including GFR. 
 
There is still debate as to how much of these observed associations are due to bicarbonate 
independent of renal function. Recent pooled data from two large randomised controlled trials [14] 
suggested that lower baseline bicarbonate concentrations correlate with faster decline in GFR, and a 
higher chance of reaching kidney failure, but also found that this association disappeared after 
adjusting for baseline GFR. In the MDRD cohort, serum bicarbonate was not associated with 
progression to end-stage renal failure or death after adjustment for baseline GFR [15]. Conversely 
other studies [16] have found that the association between low serum bicarbonate and accelerated 
decline in renal function remains even after adjustment for baseline GFR. 
 
Association with cardiovascular disease 
In the cardiovascular system, acidosis has been associated with increased levels of endothelin and 
aldosterone [17]; acidosis may also be a driver of chronic inflammation. Together, these alterations 
impair endothelial function, which is itself a major risk factor for the development of atherosclerotic 
lesions [18]. Furthermore, aldosterone is known to be important in driving left ventricular fibrosis (a 
key substrate for both arrhythmia and diastolic dysfunction), and the combined effect of increased 
blood pressure, worsening arterial stiffness as a result of these pathophysiological changes results in 
left ventricular hypertrophy – an independent risk factor for cardiovascular events that is particularly 
common in patients with CKD [19]. 
 
The association between serum bicarbonate concentration and vascular events appears more 
complicated. There is a lack of evidence of an association between low serum bicarbonate and 
increased vascular events from observational studies. Recent pooled data from two randomised 
controlled trials enrolling patients with diabetic nephropathy [14] suggested that serum bicarbonate 
was not associated with incident cardiovascular events or with incident heart failure events. Increased 
serum bicarbonate concentration may however be associated with deleterious outcomes. In the 
Chronic Renal Insufficiency Cohort (CRIC) [16], serum bicarbonate concentrations persistently >26 
mmol/L were associated with a higher rate of both heart failure and death compared to patients with 
concentrations of 22-26 mmol/L. In this cohort, a previous analysis showed no association between 
serum bicarbonate concentrations and atherosclerotic events [20]. 
 
Any association between acidosis and cardiovascular health in CKD patients may have knock-on effects 
on other important domains of health in older people. Cardiovascular disease accounts for between 
one third to a half of change in physical function with advancing age [21], and also plays an important 
role in cognitive impairment, via macrovascular stroke disease, small vessel changes and via vascular 
risk factors for Alzheimer’s disease [22]. 
 
Association with physical function 
Impaired renal function is associated with worse physical function, and this association is more 
marked in older people. Whether this is a causal relationship however is more difficult to discern, and 
the contribution of different pathophysiological components (e.g. acidosis, vitamin D system 
derangements, cardiovascular disease, uraemic toxins) to the impairment of physical function is 
difficult to disentangle. 
 
However, recent data suggests an association between serum bicarbonate concentrations and 
physical function even in patients without advanced CKD. In cross-sectional data from a sample of 
2675 patients aged 50 years and over from the NHANES cohort [23], low gait speed and quadriceps 
strength in older people were associated with lower serum bicarbonate. Adjustment for GFR and 25-
hydroxyvitamin D concentrations did not alter the results. Similar results were obtained in another 
NHANES sample, examining the relationship between serum bicarbonate and estimated maximal 
oxygen uptake (VO2max) on treadmill testing in those aged 20-49 years [24]. Again, lower serum 
bicarbonate was associated with lower VO2max even after adjustment for GFR. Importantly for patients 
with CKD, low serum bicarbonate also predicts future onset of functional limitation (defined as 
difficulty walking quarter of a mile or climbing 10 steps) in older people [25]. Those with serum 
bicarbonate <23 mmol/L were 1.6 times as likely to develop limitation as those with baseline serum 
bicarbonate of >=26 mmol/L. even after adjustment for the presence of CKD. 
 
Association with bone health 
Acidosis affects components of bone and mineral metabolism; it promotes bone resorption by 
osteoclasts while inhibiting new bone formation by osteoblasts, is associated with reduced vitamin D 
production, and may reduce parathyroid hormone release [26-28]. The risk of fracture is of particular 
relevance to the health of older people. Although CKD-related mineral bone disorder (CKD-MBD) is 
itself a risk factor for fractures [29], advancing age is the most powerful predictor of fractures and the 
incidence of fragility fractures rises exponentially with increasing age. The relationship between CKD 
and fracture in old age is less straightforward than for younger patients; although cystatin-C based 
measures of GFR suggest a relationship between lower GFR and higher fracture risk [30], creatinine-
based measures of renal function show a less clear cut relationship [31]. This is probably explicable on 
the basis that low muscle mass is a key risk factor for falls but may also be associated with low serum 
creatinine concentration, hence leading to an overestimate of GFR in such individuals and masking 
any association between creatinine-estimated GFR and fracture risk. 
 
Dissecting out the effect of acidosis on bone health and fracture risk from the effects of other 
components of mineral metabolism that are deranged in CKD is difficult; these aspects of biochemical 
derangement are often highly correlated. In patients without CKD, the evidence that dietary acid load 
is associated with bone health is weak [32], with intervention studies examining proxy measures for 
the development of osteoporosis such as urinary calcium excretion, and observational studies 
incompletely adjusting for important confounders. Analysis of the NHANES III dataset suggested that 
in the general population without CKD, higher bicarbonate concentrations were associated with 
higher bone mineral density [33]. In Japanese patients undergoing haemodialysis there was a U-
shaped relationship between bicarbonate concentration and fracture risk, with both predialysis 
bicarbonate concentrations <20 and >22 mmol/L being associated with higher incident fracture rates 
than predialysis serum bicarbonate concentrations of 21-22 mmol/L [34]; similar relationships were 
seen between acidosis and bone mineral density in a group of patients on maintenance peritoneal 
dialysis [35]. There is however a paucity of studies examining the relationship between bicarbonate 
concentrations and fracture risk specifically in patients with CKD not receiving dialysis. 
 
Other potential deleterious effects of bicarbonate 
For many patients, bicarbonate is awkward to take. The tablets are large, and multiple tablets usually 
need to be taken each day. This is a particular issue for older patients, who are more likely to have 
dysphagia or a dry mouth, and are often taking large numbers of other medications. Use of 
unencapsulated bicarbonate powder is one solution to this problem, but this approach does not lend 
itself to accurate dosing. Sodium bicarbonate contains 6 mmol of sodium per 500 mg, and this 
additional sodium load might contribute to increased blood pressure and fluid overload. There is also 
a possible adverse effect on vascular calcification [36]; raising the blood pH may make calcium and 
phosphate less soluble, thus promoting precipitation of calcium phosphate within vessel walls. 
Abdominal discomfort and bloating are recognized side effects listed in the Summary of Product 
Characteristics; this may be a result of generation of carbon dioxide in the gut via interaction with 
stomach acid. 
 
What outcomes are important to older people? 
Multimorbidity is common in older people; few older people present with a single condition, and the 
vast majority of older people will have multiple illnesses. Patients with CKD commonly suffer not only 
from conditions such as cardiovascular disease and diabetes mellitus (which often cause their CKD), 
but from conditions associated with frailty, such as falls, cognitive impairment, poor mobility and low 
mood, and the prevalence of such conditions increases with decreasing GFR [37]. Managing any given 
condition in older people, such as CKD, is thus more complex than management in younger people 
with less multimorbidity. In addition, many older people with CKD may have a life expectancy limited 
not only by CKD and cardiovascular disease, but by dementia, lung disease and frailty syndromes. The 
presence of multimorbidity commonly leads to polypharmacy; it is common for patients to have 6 or 
7 illnesses and more than 20 medications per day to take, and this situation brings with it a major risk 
of side effects, drug interactions, worsening of comorbid disease, and medication burden. 
 
How then should we manage the competing demands of multiple illnesses in older patients with CKD? 
One key principle is to focus on what outcomes are important to older people themselves; surveys 
consistently report that physical function and quality of life are key outcomes for older people [38], 
and thus our interventions should be geared towards improving these outcomes. Preventing declines 
in renal function per se may be a lower priority for some patients, although a build-up of uraemic 
toxins may contribute to the association seen between impaired renal function and frailty and poor 
physical function shown in observational studies. 
 The majority of older people with CKD will not develop kidney failure or require renal replacement 
therapy. Death from cardiovascular disease outstrips kidney failure by a factor of 6 in those aged 65 
years and over with a baseline GFR <60 mL/min/1.73m2; death from any cause (before reaching kidney 
failure) was 13 times as common as reaching kidney failure in this cohort [39]. Hence reducing the 
high rates of cardiovascular disease seen in CKD in older people is another key outcome. Preventing 
fractures – both by improving muscle function and by ameliorating osteoporosis and related CKD-MBD 
– is another key target for intervention for older people. 
 
Ideally, any intervention for older people with CKD should therefore be tested across these multiple 
domains, and should show benefits to physical function and quality of life, reduce net cardiovascular 
risk and improve CKD-MBD. Interventions that reduce the rate of decline in renal function without 
impacting favourably on these other outcomes are unlikely to provide the benefits that older patients 
wish to see from their treatment. So what does the intervention data accrued for bicarbonate therapy 
to date show when measured against these domains? 
 
Intervention data 
A small number of trials have been published examining the effect of interventions designed to 
ameliorate the effects of acidosis, but very little has been published that is of direct relevance to older 
patients. A single centre randomised controlled trial, performed in the UK, of 134 patients with GFR 
<30 mL/min/1.73 m2 provides perhaps the most relevant current evidence [40]; two years 
supplementation with a mean of 1.8 g/day oral sodium bicarbonate led to significant increases in 
serum bicarbonate (25 mmol/L vs 20 mmol/L, p<0.001), significantly fewer patients (7% vs 33%, 
p<0.001) developing kidney failure (defined as a creatinine clearance of <10ml/min/1.73m2), together 
with improvements in anthropometric measures. Reassuringly, no difference in blood pressure 
between bicarbonate and placebo groups was seen. However, patients in this trial were comparatively 
young, with a mean age of 55 years, and were overwhelmingly of Asian or African origin. 
 
A smaller, more recent Korean trial [41] also tested the effect of 3 g/day of oral sodium bicarbonate 
versus placebo in patients with GFR <30 mL/min/1.73 m2 and baseline serum bicarbonate <22 mmol/L. 
The decline in renal function appeared slower with intervention in those with GFR 15-29 mL/min/1.73 
m2, but not in those with GFR <15 mL/min/1.73 m2 over the 12 month follow up period. A nutritional 
index derived from serum albumin and the lymphocyte count showed improvement in the 
intervention group relative to controls in the GFR <15 mL/min/1.73 m2 subgroup, as did body weight. 
No changes were noted with treatment for mid-arm muscle circumference however, arguing against 
this being due to changes in lean mass. In this trial, a difference in blood pressure was seen, albeit 
non-significant due to the small size of the trial; the intervention group blood pressure increased by 
5/2.5 mmHg relative to controls after 12 months of follow-up. Again, patients in this trial were 
relatively young (mean age 54 years), and measures of physical function or quality of life were not 
reported. 
 
Current trials in this area 
What trials are currently underway, and will these trials help us to decide if bicarbonate therapy is of 
overall net benefit to older patients with CKD and acidosis? Table 1 shows trials that are currently 
recruiting, with a particular focus on the age targets and outcomes being collected. The trials currently 
in progress cover a range of ages and a range of categories of renal dysfunction. Most trials are 
targeting patients with normal or only slightly low serum bicarbonate concentrations; only the BiCARB 
trial is targeting patients exclusively with low serum bicarbonate (<22 mmol/L). 
 
Most trials are designed and powered to show differences in renal function, or to explore surrogate 
markers of renal damage. The BiCARB trial [42] aims specifically to examine the impact of bicarbonate 
on physical function and quality of life. The trial by Hostetter will examine sit to stand time – a 
powerful predictor of falls and functional impairment in older people, and will also examine grip 
strength, which is known to predict death, hospitalisation, and future need for care in older people. 
The Use of Bicarbonate in Chronic Renal Insufficiency (UBI) trial [43] will collect data on lean body 
mass (mostly represented by muscle), which although not a measure of function, is related to 
impairment as seen in studies of sarcopenia [44]. Thus the current batch of trials should provide 
evidence not only to test whether bicarbonate therapy slows the decline in renal function, but of 
perhaps greater relevance to older people, may show whether bicarbonate therapy improves physical 
function and quality of life. 
 
Although none of the trials currently underway will be large enough to show differences in all-cause 
mortality or cardiovascular events, the high rate of such events in patients with CKD might allow for 
such a signal to be detected in pooled analyses – for example, if the rate of a composite endpoint such 
as cardiovascular event or death was 30%, a pooled sample of 2100 patients would have 
approximately 80% power to detect a 25% difference in event rate. Even in the absence of such a 
signal, the current trials should be able to ascertain whether bicarbonate therapy causes blood 
pressure to rise, and whether episodes of fluid overload are more common. 
 
Conclusion 
Several lines of evidence from basic science and observational studies suggest that metabolic acidosis 
in patients with CKD has deleterious effects. Acidosis may adversely affect cardiovascular health, 
muscle function and bone health as well as accelerating decline in renal function, and impairments in 
these organ systems would be expected to have an adverse impact on physical function and quality 
of life – key outcomes for older people. There are however few intervention studies to date to show 
whether these observational data translate into relevant health gains for older people with CKD, and 
there is concern that side effects or even adverse cardiovascular effects of bicarbonate 
supplementation could negate any putative benefits. Until such data are available, it will remain 
unclear if bicarbonate therapy in older CKD patients is of net benefit; fortunately, a number of trials 
are currently underway (including one targeted specifically at older CKD patients with acidosis) that 
should give some much-needed answers to these questions. 
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 Table 1. Trials currently in progress testing the effect of bicarbonate supplementation in chronic kidney disease 
 
Trial reference 
and name 
Age 
range 
(yrs) 
Bicarbonate 
at entry 
(mmol/L) 
eGFR at entry 
(mL/min/1.73 m2) 
Dose Primary outcome Secondary outcomes Target n Follow 
up 
time 
ISRCTN09486651 
(BiCARB)[42] 
>= 60 <22 <30 3g/day vs placebo Short Physical 
Performance Battery 
Quality of life (KDQoL and 
EQ5D); decline in renal 
function, bone turnover 
markers, BP, BNP 
380 2 yrs 
 
NCT01640119 
(UBI)[43] 
>=18 >=18 <45 Up to 4g/day; 
titrated to serum 
bicarbonate of 
24-28mmol/L vs 
usual care 
Commencement of renal 
replacement therapy, or 
death 
Renal function, PTH, 
calcium, phosphate, 
albuminuria, lipids and 
homocysteine;  bone 
turnover markers, blood 
pressure, lean body mass 
by bioimpedance 
728 3 yrs 
EuDRACT  
2012-001824-36 
(SoBIC)[45] 
>=18 <21 15-44 Up to 5g/day; 
Titrated to keep 
serum 
bicarbonate >24  
mmol/L vs 
titrated to keep 
serum 
bicarbonate >20 
mmol/L 
Decline in renal function Death, recommendation 
to start renal replacement 
therapy, bone turnover 
markers 
200 2 yrs 
NCT01452412 >=19 20-25 15-45 0.4mEq/Kg ideal 
body wt/day vs 
placebo 
Insulin resistance, bone 
mineral density, sit to 
stand speed, renal tubular 
function markers 
Insulin sensitivity by 
clamp, grip strength, renal 
function, PTH, 
albuminuria, calcium, 
phosphate, 1,25OHD 
150 1 yr 
Pending 
registration: 
(BASE trial) 
18-85 20-28 20-44 or 
45-59 + ACR >100 
mg/g 
0.5 vs 0.8 mEq/Kg 
lean body wt/day 
Adherence to dose Urinary ammonium 
excretion 
192 28 
wks 
NCT01574157 >=18 
with 
Type 2 
diabetes 
22-28 15-89 + ACR >30 
mg/g 
0.5 mEq/Kg lean 
body wt/day vs 
placebo 
Urinary TGF-beta Urinary complement 
components 
74 6 
mths 
NCT02031770 40-70 16-19 15-29 2-3x/day dosing 
to raise serum 
bicarbonate to 
>=23 mmol/L vs 
usual care 
(crossover design) 
Brachial artery flow-
mediated dilatation 
- 20 14 
wks 
ACR: Albumin/Creatinine ratio. BP: Blood pressure. BNP: B-type natriuretic peptide. PTH: parathyroid hormone, TGF-beta: transforming growth factor beta 
1,25OHD: 1,25-hydroxyvitamin D 
 
 
